Current trends in the assessment and somatic treatment of resistant/refractory major depression: An overview

References

• Fava M., Davidson K. G. Definition and epidemiology of treatment‐resistant depression. Psychiatr Clin North Am 1996; 19: 179–200
   PubMed Web of Science ®Google Scholar
• O'Reardon J. P., Amsterdam J. D. Overview of treatment‐resistant depression and its management. Treatment‐Resistant Mood Disorders, J. D Amsterdam, M Hornig, A. A Nierenberg. Cambridge University Press, New York 2001; 30–45
   Google Scholar
• O'Reardon J. P., Brunswick D. J., Amsterdam J. D. Treatment‐resistant depression in the age of serotonin: evolving strategies. Curr Opin Psychiatry 2000; 13: 93–8
   Google Scholar
• Berman R. M., Narasimhan M., Charney D. S. Treatment‐refractory depression: definitions and characteristics. Depress Anxiety 1997; 5: 154–64
   Google Scholar
• O'Reardon J. P., Amsterdam J. D. Treatment‐resistant depression: progress and limitations. Psychiatr Ann 1998; 28: 633–40
   Web of Science ®Google Scholar
• Bird D., Haddad P. M., Dursun S. M. An overview of the definition and management of treatment‐resistant depression. Klin Psikofarmakol Bul 2002; 12: 92–101
   Google Scholar
• Fava M. Diagnosis and definition of treatment‐resistant depression. Biol Psychiatry 2003; 53: 649–59
   PubMed Web of Science ®Google Scholar
• Ananth J. Treatment‐resistant depression. Psychother Psychosom 1998; 67: 61–70
   PubMed Web of Science ®Google Scholar
• Berlim M. T., Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 2007; 17: 696–707
   PubMed Web of Science ®Google Scholar
• Souery D., Lipp O., Massat I., Mendlewicz J. The characterization and definition of treatment‐resistant mood disorders. Treatment‐Resistant Mood Disorders, J. D Amsterdam, M Hornig, A. A Nierenberg. Cambridge University Press, New York 2001; 3–29
   Google Scholar
• Berlim M. T., Turecki G. Definition, assessment and staging of treatment resistant/refractory major depression: a review of current concepts and methods. Can J Psychiatry 2006; 51: 875–82
   Google Scholar
• Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9: 83–91
   PubMed Web of Science ®Google Scholar
• Fagiolini A., Kupfer D. J. Is treatment‐resistant depression a unique subtype of depression?. Biol Psychiatry 2003; 53: 640–8
   PubMed Web of Science ®Google Scholar
• Rush A. J., Thase M. E., Dube S. Research issues in the study of difficult‐to‐treat depression. Biol Psychiatry 2003; 53: 743–53
   PubMed Web of Science ®Google Scholar
• Keller M. B. Issues in treatment‐resistant depression. J Clin Psychiatry 2005; 66: 5–12
   PubMed Web of Science ®Google Scholar
• Kornstein S. G., Schneider R. K. Clinical features of treatment‐resistant depression. J Clin Psychiatry 2001; 62(Suppl 16)18–25
   PubMedGoogle Scholar
• Sackeim H. A. The definition and meaning of treatment‐resistant depression. J Clin Psychiatry 2001; 62(Suppl 16)10–7
   PubMedGoogle Scholar
• Rothschild A. J. Challenges in the treatment of depression with psychotic features. Biol Psychiatry 2003; 53: 680–90
   PubMed Web of Science ®Google Scholar
• Ayuso‐Gutierrez J. L. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World J Biol Psychiatry 2005; 6(Suppl 2)31–7
   Google Scholar
• Fleck M. P., Horwath E. Pharmacologic management of difficult‐to‐treat depression in clinical practice. Psychiatr Serv 2005; 56: 1005–11
   PubMed Web of Science ®Google Scholar
• Rush A. J., Kraemer H. C., Sackeim H. A., Fava M., Trivedi M. H., Frank E., et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31: 1841–53
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Nierenberg A. A., DeCecco L. M. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment‐resistant depression. J Clin Psychiatry 2001; 62(Suppl 16)5–9
   PubMedGoogle Scholar
• Pridmore S., Turnier‐Shea Y. Medication options in the treatment of treatment‐resistant depression. Aust N Z J Psychiatry 2004; 38: 219–25
   PubMed Web of Science ®Google Scholar
• Souery D., Papakostas G. I., Trivedi M. H. Treatment‐resistant depression. J Clin Psychiatry 2006; 67(Suppl 6)16–22
   PubMed Web of Science ®Google Scholar
• Fava M., Rush A. J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006; 75: 139–53
   PubMed Web of Science ®Google Scholar
• Nelson J. C. Overcoming treatment resistance in depression. J Clin Psychiatry 1998; 59(Suppl 16)13–9, discussion 40–2
   PubMed Web of Science ®Google Scholar
• Nelson J. C. Managing treatment‐resistant major depression. J Clin Psychiatry 2003; 64(Suppl 1)5–12
   PubMed Web of Science ®Google Scholar
• Nierenberg A. A., Katz J., Fava M. A critical overview of the pharmacologic management of treatment‐resistant depression. Psychiatr Clin North Am 2007; 30: 13–29
   PubMed Web of Science ®Google Scholar
• Thase M., Rush A. J. Treatment‐resistant depression. Psychopharmacology: The Fourth Generation of Progress, 4th ed, F. E Bloom, D. J Kupfer. Raven Press, New York 1995
   Google Scholar
• Nierenberg A. A., Fava M., Trivedi M. H., Wisniewski S. R., Thase M. E., McGrath P. J., et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1519–30, quiz 1665
   PubMed Web of Science ®Google Scholar
• Trivedi M. H., Fava M., Wisniewski S. R., Thase M. E., Quitkin F., Warden D., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243–52
   PubMed Web of Science ®Google Scholar
• Moreno F. A., Gelenberg A. J., Bachar K., Delgado P. L. Pindolol augmentation of treatment‐resistant depressed patients. J Clin Psychiatry 1997; 58: 437–9
   PubMed Web of Science ®Google Scholar
• Perez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double‐blind, randomized, placebo‐controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999; 56: 375–9
   PubMed Web of Science ®Google Scholar
• Fawcett J., Kravitz H. M., Zajecka J. M., Schaff M. R. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment‐refractory depression. J Clin Psychopharmacol 1991; 11: 127–32
   PubMed Web of Science ®Google Scholar
• Price L., Carpenter L., Rasmussen S. Drug combining strategies. Treatment‐Resistant Mood Disorders, J Amsterdam, M Hornig, A Nierenberg. Cambridge University Press, Cambridge 2001
   Google Scholar
• Glassman A. H., Kantor S. J., Shostak M. Depression, Delusions, and Drug Response. Am J Psychiatry 1975; 132: 716–9
   PubMed Web of Science ®Google Scholar
• Nelson J. C., Bowers M. B Jr. Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 1978; 35: 1321–8
   PubMed Web of Science ®Google Scholar
• Ostroff R. B., Nelson J. C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256–9
   PubMed Web of Science ®Google Scholar
• Shelton R. C., Tollefson G. D., Tohen M., Stahl S., Gannon K. S., Jacobs T. G., et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–4
   PubMed Web of Science ®Google Scholar
• Razani J., White K. L., White J., Simpson G., Sloane R. B., Rebal R., et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 1983; 40: 657–61
   PubMed Web of Science ®Google Scholar
• White K., Simpson G. Combined MAOI‐tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1981; 1: 264–82
   PubMed Web of Science ®Google Scholar
• Shelton R. C., Tomarken A. J. Can recovery from depression be achieved?. Psychiatr Serv 2001; 52: 1469–78
   PubMedGoogle Scholar
• Cappiello A., McDougle C. J., Malison R. T., Heninger G. R., Price L. H. Yohimbine augmentation of fluvoxamine in refractory depression: a single‐blind study. Biol Psychiatry 1995; 38: 765–7
   Google Scholar
• Dam J., Ryde L., Svejso J., Lauge N., Lauritsen B., Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998; 31: 48–54
   PubMed Web of Science ®Google Scholar
• Carpenter L. L., Yasmin S., Price L. H. A double‐blind, placebo‐controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51: 183–8
   PubMed Web of Science ®Google Scholar
• Petrides G., Fink M., Husain M. M., Knapp R. G., Rush A. J., Mueller M., et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001; 17: 244–53
   PubMed Web of Science ®Google Scholar
• Pearlman C. Electroconvulsive therapy in clinical psychopharmacology. J Clin Psychopharmacol 2002; 22: 345–6
   PubMed Web of Science ®Google Scholar
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta‐analysis. Lancet 2003; 361: 799–808
   PubMed Web of Science ®Google Scholar
• Folkerts H. W., Michael N., Tolle R., Schonauer K., Mucke S., Schulze‐Monking H. Electroconvulsive therapy vs. paroxetine in treatment‐resistant depression—a randomized study. Acta Psychiatr Scand 1997; 96: 334–42
   PubMed Web of Science ®Google Scholar
• Rush A. J., Sackeim H. A., Marangell L. B., George M. S., Brannan S. K., Davis S. M., et al. Effects of 12 months of vagus nerve stimulation in treatment‐resistant depression: a naturalistic study. Biol Psychiatry 2005; 58: 355–63
   PubMed Web of Science ®Google Scholar
• Sackeim H. A., Rush A. J., George M. S., Marangell L. B., Husain M. M., Nahas Z., et al. Vagus nerve stimulation (VNS) for treatment‐resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001; 25: 713–28
   PubMed Web of Science ®Google Scholar
• Rush A. J., George M. S., Sackeim H. A., Marangell L. B., Husain M. M., Giller C., et al. Vagus nerve stimulation (VNS) for treatment‐resistant depressions: a multicenter study. Biol Psychiatry 2000; 47: 276–86
   PubMed Web of Science ®Google Scholar
• Rush A. J., Marangell L. B., Sackeim H. A., George M. S., Brannan S. K., Davis S. M., et al. Vagus nerve stimulation for treatment‐resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347–54
   PubMed Web of Science ®Google Scholar
• Loo C. K., Mitchell P. B. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Disord 2005; 88: 255–67
   PubMed Web of Science ®Google Scholar
• Herrmann L. L., Ebmeier K. P. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. J Clin Psychiatry 2006; 67: 1870–6
   PubMed Web of Science ®Google Scholar
• Mayberg H. S., Lozano A. M., Voon V., McNeely H. E., Seminowicz D., Hamani C., et al. Deep brain stimulation for treatment‐resistant depression. Neuron 2005; 45: 651–60
   PubMed Web of Science ®Google Scholar
• Peselow E. D., Filippi A. M., Goodnick P., Barouche F., Fieve R. R. The short‐ and long‐term efficacy of paroxetine HCl: A. Data from a 6‐week double‐blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull 1989; 25: 267–71
   Google Scholar
• Thase M. E., Rush A. J., Howland R. H., Kornstein S. G., Kocsis J. H., Gelenberg A. J., et al. Double‐blind switch study of imipramine or sertraline treatment of antidepressant‐resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233–9
   PubMed Web of Science ®Google Scholar
• Nierenberg A. A., Papakostas G. I., Petersen T., Kelly K. E., Iacoviello B. M., Worthington J. J., et al. Nortriptyline for treatment‐resistant depression. J Clin Psychiatry 2003; 64: 35–9
   PubMedGoogle Scholar
• Poirier M. F., Boyer P. Venlafaxine and paroxetine in treatment‐resistant depression. Double‐blind, randomised comparison. Br J Psychiatry 1999; 175: 12–6
   PubMed Web of Science ®Google Scholar
• Kaplan E. M. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open‐label, uncontrolled study. Clin Ther 2002; 24: 1194–200
   Google Scholar
• McGrath P., Fava M., Stewart J. Bupropion for SSRI‐resistant depression. 2000, In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; San Juan, Puerto Rico
   Google Scholar
• Joffe R. T., Levitt A. J., Sokolov S. T., Young L. T. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996; 57: 114–5
   PubMed Web of Science ®Google Scholar
• Rush A. J., Trivedi M. H., Wisniewski S. R., Stewart J. W., Nierenberg A. A., Thase M. E., et al. Bupropion‐SR, sertraline, or venlafaxine‐XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231–42
   PubMed Web of Science ®Google Scholar
• Fava M., Dunner D. L., Greist J. H., Preskorn S. H., Trivedi M. H., Zajecka J., et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open‐label trial. J Clin Psychiatry 2001; 62: 413–20
   PubMed Web of Science ®Google Scholar
• Nolen W., Hoencamp E., Haffmans P. Classical and selective monoamine oxidase inhibitors in refractory major depression. Refractory Depression—Current Strategies and Future Directions, W Nolen, J Zohar, S Roose. John Wiley & Sons, New York 1994
   Google Scholar
• McGrath P. J., Stewart J. W., Fava M., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1531–41, quiz 1666
   PubMed Web of Science ®Google Scholar
• Rush A. J., Fava M., Wisniewski S. R., Lavori P. W., Trivedi M. H., Sackeim H. A., et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119–42
   PubMedGoogle Scholar
• Rush A. J., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., et al. Acute and Longer‐Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry 2006; 163: 1905–17
   PubMed Web of Science ®Google Scholar
• Trivedi M. H., Rush A. J., Wisniewski S. R., Nierenberg A. A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement‐based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40
   PubMed Web of Science ®Google Scholar
• Fava M., Rush A. J., Wisniewski S. R., Nierenberg A. A., Alpert J. E., McGrath P. J., et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163: 1161–72
   PubMed Web of Science ®Google Scholar
• Nelson J. C. The STAR*D Study: A Four‐Course Meal That Leaves Us Wanting More. Am J Psychiatry 2006; 163: 1864–6
   PubMed Web of Science ®Google Scholar
• Thase M. E., Friedman E. S., Biggs M. M., Wisniewski S. R., Trivedi M. H., Luther J. F., et al. Cognitive therapy versus medication in augmentation and switch strategies as second‐step treatments: a STAR*D report. Am J Psychiatry 2007; 164: 739–52
   PubMed Web of Science ®Google Scholar
• Kennedy S. H., Lam R. W., Cohen N. L., Ravindran A. V. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46(Suppl 1)38S–58S
   Google Scholar